Search
Bencyclane
go.drugbank.com/drugs/DB13488ExperimentalA vasodilator agent found to be effective in a variety of peripheral circulation disorders. It has various other potentially useful pharmacological effects.
Synonyms: 3-((1-Benzylcycloheptyl)oxy)-N,N-dimethylpropylaminBMS-986020
go.drugbank.com/drugs/DB14948InvestigationalBMS-986020 is under investigation in clinical trial NCT02017730 (To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy
Zunsemetinib
go.drugbank.com/drugs/DB16502InvestigationalAdditionally, ATI-450 was studied in a terminated trial (NCT05511519) to treat patients with psoriatic arthritis.
Tiletamine
go.drugbank.com/drugs/DB11549ExperimentalVet approvedTiletamine is chemically similar to another dissociative anesthetic, ketamine. Tiletamine hydrochloride, the salt form, exists as odorless white crystals.
PZM21
go.drugbank.com/drugs/DB14030ExperimentalPZM21 is a novel μ-opioid receptor (MOPr) ligand that has been reported to induce minimal arrestin recruitment and be devoid of the respiratory depressant effects characteristic of classical μ-opioid ligands
(1R)-1-(2-thienylacetylamino)-1-phenylmethylboronic acid
go.drugbank.com/drugs/DB08552ExperimentalThis compound belongs to the benzenes and substituted derivatives. These are aromatic compounds containing at least one benzene ring. This medication targets the protein beta-lactamase.
Maridebart Cafraglutide
go.drugbank.com/drugs/DB19339InvestigationalMaridebart Cafraglutide is under investigation in clinical trial NCT05669599 (Dose-ranging Study to Evaluate the Efficacy, Safety, and Tolerability of AMG 133 in Adult Subjects With Overweight or Obesity
HPV-16 trojan peptide vaccine
go.drugbank.com/drugs/DB17496InvestigationalHPV-16 trojan peptide vaccine is an investigational cancer immunotherapy consisting of a novel Trojan peptide complex, composed of human papilloma virus 16 (HPV 16) epitopes, to stimulate antigen-specific
ABBV-514
go.drugbank.com/drugs/DB17586InvestigationalABBV-514 is in development for the treatment of non-small cell lung cancer (NSCLC) and head and neck squamous cell carcinoma (HNSCC) as a single agent and in combination with a PD-1 inhibitor.[L45464]